You searched for "AMD"

827 results found

Systemic pharmacology of intravitreal anti-VEGF

This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...

Macular atrophy with aflibercept

The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...

Zero Residual™ reduces the cost of intravitreal injections

At a time when patient numbers are increasing and budgets are stretched, reducing costs in expensive wet-AMD treatments can be achieved with the Zero Residual™ Concept.

Ophthalmology (third edition)

If you are an ophthalmologist who enjoys books with coloured pictures, you’re no lone wolf. The third edition of Lang’s Ophthalmology will definitely pique your primal ophthalmologist instincts. You will be drawn to its soft-bound yet sturdy looking exterior. Flicking...

The effects of anti-VEGF therapy for NvAMD on retinal vasculature

This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...

Advances and developments in medical retina

The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...

Eye Capacity: clinical need should drive ophthalmic service provision

Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Telemedicine strategies in ophthalmology: harnessing established and emerging technologies for lasting solutions

The author considers recent progress and shares insights from leading practitioners in telemedicine applications and digital technology strategies. Amidst COVID-19 and combined mitigation and suppression measures, hospitals and clinics have responded rapidly to strengthen telemedicine strategies and virtual healthcare services...

Catch up with the Heidelberg Engineering Academy educational webinars

Since the beginning of April 2020, the Heidelberg Engineering Academy has hosted eight educational webinars covering a wide range of topics including the impact of COVID-19 on ophthalmology services, using OCT to evaluate patients for retinal pathologies and glaucoma, and the latest ophthalmic research studies.

In conversation with Robert MacLaren

Professor Robert MacLaren gave the Keeler Lecture at the Royal College of Ophthalmologists Annual Meeting in May 2019 on gene therapy for retinitis pigmentosa. We caught up with him afterwards to find out more. What are the key messages of...

Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions

Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...